Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data for Vanderbilt triple-negative breast cancer subtype classification

ABSTRACT: Expression data for Vanderbilt triple-negative breast cancer subtype classification

PROVIDER: PRJNA939561 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression data for Vanderbilt triple-negative breast cancer subtype classification

Project description:This study developed a triple-negative breast cancer (TNBC) surrogate subtype classification that represents TNBC subtypes based on the Vanderbilt subtype classification The web-based subtyping tool TNBCtype was used to classify the TNBC cohort into Vanderbilt subtypes

2023-03-04 | GSE226289 | GEO

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BRCAness.

Project description:Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BRCAness.

| PRJNA470674 | ENA

Differential analysis of nucleolar proteomics in triple negative breast cancer

Project description:Breast cancer is one of the most common cancers in women. Of the different subtypes of breast cancer, the triple negative breast cancer subtype of breast cancer is the most aggressive. A proteomic screen of nucleolar content across breast cancer subtypes found that triple negative breast cancer cell lines have a distinct nucleolar proteome signature in comparison to non-TNBC breast cancer cell lines.

2021-03-05 | PXD021201 | Pride

Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression.

Project description:Medullary breast carcinoma, a triple-negative breast cancer subtype associated with BCLG overexpression.

| PRJNA466799 | ENA

Estrogen Receptor beta (ERβ) interactome in triple negative breast cancer cells nuclei

Project description:Breast cancer (BC) is the second most common type of cancer in women and one of the leading causes of cancer-related deaths worldwide. BC classification is based on the detection of three main histological markers: estrogen receptor alpha (ERα), progesterone receptor (PR) and the amplification of epidermal growth factor receptor 2 (HER2/neu). A specific BC subtype, named triple-negative BC (TNBC), lacks the aforementioned markers but a fraction of them express the estrogen receptor beta (ERβ). To investigate the functional role of ERβ in these tumors, interaction proteomics coupled to mass spectrometry (MS) was applied to deeply characterize the nuclear interactors partners in MDA-MD-468 and HCC1806 TNBC cells.

2019-12-03 | PXD014468 | Pride

FZD7 Plays a Critical Role in Triple Negative Breast Cancer Proliferation

Project description:Breast cancer is genetically and clinically heterogeneous. Triple negative cancer (TNBC) is a subtype of breast cancer usually associated with poor outcome and lack of benefit from target therapy. A pathway analysis in a microarray study was performed using TNBC compared with non-triple negative breast cancer (non-TNBC). Overexpression of several Wnt pathway genes, such as frizzled homolog 7 (FZD7), Low density lipoprotein receptor-related protein 6 (LRP6) and transcription factor 7 (TCF7) has been observed in TNBC. Focus was given to the Wnt pathway receptor, FZD7. To validate its function, inhibition of FZD7 using FZD7shRNA was carried out. Notably decreased cell proliferation, suppressed invasiveness and colony formation in triple negative MDA-MB-231 and BT-20 cells were observed. Mechanism study indicated that these effects occurred through silencing the canonical Wnt signaling pathway, as evidenced by loss of nuclear accumulation of ï?¢-catenin and decreased transcriptional activity of TCF7. In vivo study revealed that FZD7shRNA significantly suppressed the tumor formation in xenotransplation mice due to decrease cell proliferation. Our finding suggests that FZD7 involved canonical Wnt signaling pathway is essential for tumorigenesis of TNBC. Thus, FZD7 may be a biomarker and a potential therapeutic target for triple negative breast cancer. 14 pretreatment non-triple negative breast tumors compare with 5 triple negative breast tumor.

2011-06-01 | E-GEOD-27447 | biostudies-arrayexpress

Long non-coding RNA landscape of patients biopsies from advanced Triple Negative Breast Cancer

Project description:The response to specific treatments relies on precise biomarkers, thereby avoiding undesirable toxicities and diminishing the cost. Due to the lack of treatment options in triple-negative breast cancer, it is crucial to search biomarkers with reasonable specificity and sensibility to recognize clusters of patients who could benefit from the cutting-edge oncologist treatments available nowadays. Microarrays were used to detail the global gene expression program to stratified TNBC patients according to TNBCtype software developed by Vanderbilt University and then identified lncRNAs expressed differentially through the TNBC subtypes.

2021-06-04 | GSE176128 | GEO

Comprehensive genomic analysis identify novel subtypes and targets of triple-negative breast cancer (67 not triple-negative tumors)

Project description:Recent meta-analyses suggest triple-negative breast cancer (TNBC) is a heterogenous disease. In this study we sought to define these TNBC subtypes and identify subtype-specific markers and targets. We identified and confirmed four distinct, stable TNBC subtypes: (1) Luminal-AR (LAR); 2) Mesenchymal (MES); 3) Basal-Like Immune-Suppressed (BLIS), and 4) Basal-Like Immune-Activated (BLIA).

2015-12-23 | GSE76274 | GEO

Pam50 of a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

Project description:Our aims is correlate the data and classification of the subtype breast cancer obtained with the Pam50 assay with the data obtained from the analysis of the same patients RNAseq

2021-08-07 | GSE181548 | GEO

RNAseq of a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification

2021-08-07 | GSE181466 | GEO